L. Hunsicker

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
2023102 citationsauthor #55
Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study.
202236 citationsauthor #10
Risk Prediction for Delayed Allograft Function: Analysis of the Deterioration of Kidney Allograft Function (DeKAF) Study Data
20212 citationsauthor #8
361-OR: BETA-2 Score Is Highly Predictive of Graft Function after Islet Transplant: Analysis of Clinical Islet Transplant Consortium Trials
20200 citationsauthor #8
Inflammation in areas of fibrosis: The DeKAF prospective cohort
202021 citationsauthor #7
Phase 3 trial of human islet‐after‐kidney transplantation in type 1 diabetes
202072 citationsauthor #16
i‐IFTA and chronic active T cell–mediated rejection: A tale of 2 (DeKAF) cohorts
202021 citationsauthor #10
358-OR: ß-Cell Function and Insulin Sensitivity with Islet Alone and Islet-after-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation (CIT) Consortium
20200 citationsauthor #10
360-OR: BETA-2 Score Is Highly Correlated with Acute Insulin Response to Intravenous Glucose: An Analysis of the Clinical Islet Transplantation Consortium Trials
20202 citationsauthor #8
Small Split Pediatric Kidneys to Expand the Donor Pool: An analysis of Scientific Registry of Transplant Recipients (SRTR) Data.
201922 citationsauthor #4
Long‐term follow‐up of the DeKAF cross‐sectional cohort study
201926 citationsauthor #9
Late Graft Loss After Kidney Transplantation: Is “Death With Function” Really Death With a Functioning Allograft?
201933 citationsauthor #5
Late graft failure after kidney transplantation as the consequence of late versus early events
201843 citationsauthor #3
Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia
201898 citationsauthor #5
Purified Human Pancreatic Islets, CIT Culture Media with Lisofylline or Exenatide.
20171 citationsauthor #109
B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients
201710 citationsauthor #8
The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis .
20177 citationsauthor #8
Erratum. National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 2016;65:3418–3428
20175 citationsauthor #13
Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.
201726 citationsauthor #10
Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial.
201628 citationsauthor #8
National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities
2016161 citationsauthor #13
Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
201624 citationsauthor #6
Short Stature and Access to Lung Transplantation: Reducing Disparities by Changing to a Lung Size-based Allocation Mechanism.
20163 citationsauthor #2
BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
201478 citationsauthor #5
CARDIAC TROPONIN I AND B-TYPE NATRIURETIC PEPTIDE PREDICT CLINICAL OUTCOMES IN STABLE RENAL TRANSPLANT RECIPIENTS
20140 citationsauthor #8
Higher Income Associated With Lower Risk of Liver Disease But Higher Likelihood of Listing for Liver Transplantation.: Abstract# B827
20140 citationsauthor #3
High MELD Score Has No Effect On the Magnitude of the Mortality Increase Observed With Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement.: Abstract# 708
20140 citationsauthor #4
Completion of the first FDA phase 3 multicenter trial of Islet transplantation in type 1 diabetes by the NIH CIT consortium
20143 citationsauthor #23
Cardiac size and sex-matching in heart transplantation : size matters in matters of sex and the heart.
2014200 citationsauthor #3
Donor-recipient size matching and survival after lung transplantation. A cohort study.
201373 citationsauthor #9
Regional Variability in Liver Waiting List Removals Causes False Ascertainment of Waiting List Deaths
201316 citationsauthor #2
Lung size mismatch and survival after single and bilateral lung transplantation.
201351 citationsauthor #9
Deceased Donor Liver Allocation: Cutting the Gordian Knot
20130 citationsauthor #2
Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.
201386 citationsauthor #8
Kidney Function and Risk of Cardiovascular Disease and Mortality in Kidney Transplant Recipients: The FAVORIT Trial
2012127 citationsauthor #6
Pyridorin in type 2 diabetic nephropathy.
2012141 citationsauthor #6
Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study
2011143 citationsauthor #3
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
2011119 citationsauthor #4
Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
2011184 citationsauthor #5
Histopathologic Clusters Differentiate Subgroups Within the Nonspecific Diagnoses of CAN or CR: Preliminary Data from the DeKAF Study
201091 citationsauthor #8
INFLAMMATION IN AREAS OF TUBULAR ATROPHY (IATR) PREDICTS KIDNEY ALLOGRAFT FAILURE: 1202
20100 citationsauthor #9
Pathological and Clinical Characterization of the ‘Troubled Transplant’: Data from the DeKAF Study
2010127 citationsauthor #9
LATE ACUTE REJECTION - AN IMPACT ON THE LONG-TERM KIDNEY ALLOGRAFT SURVIVAL: 279
20101 citationsauthor #10
Inflammation in Areas of Tubular Atrophy in Kidney Allograft Biopsies: A Potent Predictor of Allograft Failure
2010207 citationsauthor #12
Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure
2010480 citationsauthor #10
Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
200950 citationsauthor #3
The disadvantage of being fat.
20086 citationsauthor #2
Physician access and early nephrology care in elderly patients with end-stage renal disease.
200812 citationsauthor #6
47-W: A case of antibody mediated rejection from anti-donor HLA-Cw antibody
20081 citationsauthor #4
USE OF CARDIOPROTECTIVE MEDICATIONS IN KIDNEY TRANSPLANT RECIPIENTS: PRELIMINARY OBSERVATIONS FROM THE DETERIORATION OF KIDNEY ALLOGRAFT FUNCTION (DEKAF) STUDY: 609
20080 citationsauthor #8
OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation?
200847 citationsauthor #2
National Kidney Foundation 2007 Spring Clinical Meetings Abstract246: Short-Term Survival Effect of Early Nephrology Care Prior to Dialysis Initiation in Elderly Patients with End-Stage Renal Disease
20070 citationsauthor #6
Short‐ and Long‐Term Outcomes with the Use of Kidneys and Livers Donated after Cardiac Death
200772 citationsauthor #2
52: Lack of Association of Conventional Cardiovascular Screening Tests with Survival of Patients on Hemodialysis (HD)
20070 citationsauthor #3
A Report of the Lisbon Conference on the Care of the Kidney Transplant Recipient
2007115 citationsauthor #12
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective.
2006519 citationsauthor #6
PUK7 FACTORS INFLUENCING EARLY NEPHROLOGY CARE PRIOR TO HEMODIALYSIS INITIATION AMONG ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE
20060 citationsauthor #6
The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
200627 citationsauthor #7
The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension
200657 citationsauthor #7
Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
200664 citationsauthor #4
Erratum: Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial (Clinical Trials 2 (400-412))
20060 citationsauthor #8
Effect of dialysis center profit-status on patient survival: a comparison of risk-adjustment and instrumental variable approaches.
200665 citationsauthor #3
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
200517 citationsauthor #2
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
2005379 citationsauthor #4
C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.
200521 citationsauthor #2
Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial
200552 citationsauthor #8
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
2005322 citationsauthor #2
Should hypertension be treated with a renin-angiotensin blocker?
20050 citationsauthor #2
Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trial
200530 citationsauthor #8
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
2005375 citationsauthor #9
Outcomes for Living Donor and Cadaver Donor Kidney Transplantation
20040 citationsauthor #2
EFFECT OF A SUCCESSFUL PANCREATIC TRANSPLANT ON PATIENT SURVIVAL
20040 citationsauthor #2
K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease
20041,006 citationsauthor #52
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
2004130 citationsauthor #7
Emerging Trends for Prevention and Treatment of Diabetic Nephropathy
200429 citationsauthor #1
The consequences and costs of chronic kidney disease before ESRD.
200467 citationsauthor #1
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
200451 citationsauthor #1
An Evidence-Based Approach: The Emerging Role of Renal Protection in Hypertension; A Focus on Clinical and Economic Factors That Impact Formulary Decision Making
20043 citationsauthor #4
Kidney and blood pressure regulation.
20040 citationsauthor #2
Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.
200434 citationsauthor #2
The economics of deceased donor transplantation: a microcosm of health care.
20043 citationsauthor #1
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
20032,591 citationsauthor #41
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy
2003408 citationsauthor #2
The stability of the glomerular filtration rate after renal transplantation is improving.
2003106 citationsauthor #2
Estimating the number of potential organ donors in the United States.
2003228 citationsauthor #8
Prevention of Post‐transplant Cardiovascular Disease – Report and Recommendations of an Ad Hoc Group 1
200276 citationsauthor #15
Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy.
200217 citationsauthor #2
K/DOQI clinical practice guidelines for chronic kidney disease
2002132 citationsauthor #55
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
200213,091 citationsauthor #55
A CLINICAL TRIAL IN PATIENTS WITH OVERT TYPE 2 DIABETIC NEPHROPATHY
20020 citationsauthor #5
Bone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls
200220 citationsauthor #5
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
20015,824 citationsauthor #2
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.
2001346 citationsauthor #4
Delayed Graft Function: State of the Art, November 10–11, 2000. Summit Meeting, Scottsdale, Arizona, USA
2001180 citationsauthor #2
ESTIMATING ORGAN DONOR POTENTIAL: AN EMPIRICAL PROFILE OF THE UNITED STATES.: Abstract# 284 Poster Board #‐Session: P131‐I
20001 citationsauthor #6
Comparison of the Serum and Intracellular Pharmacokinetics of Azithromycin in Healthy and Diabetic Volunteers
200010 citationsauthor #5
LONG TERM PATIENT AND KIDNEY SURVIVAL OF SIMULTANEOUS PANCREAS‐KIDNEY TRANSPLANT (SPK) VERSUS KIDNEY TRANSPLANTS WITH EARLY PANCREAS FAILURE.: Abstract# 376 Poster Board #‐Session: P16‐II
20001 citationsauthor #3
The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
2000140 citationsauthor #4
DACLIZUMAB PERMITS DELAYED INTRODUCTION OF CALCINEURIN INHIBITORS IN RENAL TRANSPLANT RECIPIENTS AT RISK FOR DELAYED GRAFT FUNCTION.: Abstract# 175 Poster Board #‐Session: P22‐I
20004 citationsauthor #3
Sudden Hearing Loss Associated with Tacrolimus in a Kidney‐Pancreas Allograft Recipient
199915 citationsauthor #6

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT